Company Overview and News

 
TECH / Bio-Techne Corp FORM DEF 14A

2018-09-11 sec.gov
tech20180906_def14a.htm Table of Contents
TECH

 
TECH / Bio-Techne Corp FORM DEFA14A

2018-09-11 sec.gov
tech20180906_defa14a.htm
TECH

 
TECH / Bio-Techne Corp FORM 8-K (Current Report)

2018-09-05 sec.gov
tech20180904_8k.htm
TECH

306
Stocks To Watch: Time To Talk Valuation

2018-09-01 seekingalpha - 8
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
HIBB JWN DKS AVGO APRN PCB SODA AMC TMUS PDYPF AKCA JONE COUP SOLO REV MESA CZR LJPC VZ HEAR FCAU BRC MGM GCO FB ULTA IGT TM IRBT VCNX CTXR LB GMVHF MTCH DBX KS JNEEP AAPL USAK TSG ZAGG PRTY KSU DDS MRVL COOL HMC GBX TSCO DSKE MU DG WRK BYD LOW LRCX TXN CTRP TWX HA SKYW GNC RCL RH UAL PFCF AMZN TWTR CATO BKS VLKAY OSTK AAL BKE BBY GWRE MDLZ GME ON NSC NAV GOOGL QCOM HD XLNX CHDN CPB WDAY FND JBLU QSII WIMHY ALK ADBE MDXG GM GOGO CROX DAL CWH WIMHF F TECH PANW COST M SAVE WMH W S PEP URBN

 
TECH / Bio-Techne Corp FORM 10-K (Annual Report)

2018-08-27 sec.gov
tech20180630_10k.htm
TECH

 
TECH / Bio-Techne Corp FORM 8-K (Current Report)

2018-08-07 sec.gov
tech20180803_8k.htm
TECH

 
TECH / Bio-Techne Corp FORM 8-K (Current Report)

2018-08-02 sec.gov
tech20180801_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
TECH

5
Gentherm Welcomes Additional Members to its Board of Directors

2018-08-01 globenewswire
NORTHVILLE, Mich., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ: THRM), the global market leader and developer of innovative thermal management technologies, today announced that Charles Kummeth has been appointed to the Company’s Board of Directors effective August 1, 2018, and John Stacey was elected to the Company’s Board of Directors during the 2018 Gentherm annual meeting that was held on May 18, 2018.
BUD MTSI TMO TECH AHBIF THRM

 
5 Tips for Making Money in Penny Stocks

2018-07-12 investorplace
First, let’s get something straight. The definition of penny stocks is entirely subjective. What I think constitutes a risky penny stock, you might feel is a robust, thriving enterprise.
TECH MNST KO

 
TECH / Bio-Techne Corp / BlackRock Inc. - null (Passive Investment)

2018-07-10 sec.gov
us09073m1045_070518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) BIO-TECHNE CORPORATION -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 09073M104 -------------------------------------------------------- (CUSIP Number) June 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover
TECH

 
TECH / Bio-Techne Corp / BlackRock Inc. - null (Passive Investment)

2018-07-10 sec.gov
us09073m1045_070518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) BIO-TECHNE CORPORATION -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 09073M104 -------------------------------------------------------- (CUSIP Number) June 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover
TECH

1
TECH / Bio-Techne Corp FORM 8-K (Current Report)

2018-06-26 sec.gov
tech20180625_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
TECH

1
TECH / Bio-Techne Corp null

2018-05-31 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"[email protected],"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S,V M.#DO3R Q,2]%(#(X,S([email protected],B]4(#,S,[email protected]@6R [email protected],30X73X^#65N M9&]B:@[email protected](" @(" @(" @(" @(" @(" @#0HQ-B P(&]B:@T\/"]$96-O9&50 M87)M7!E+UA2968O5ULQ(#(@,5T^/G-T('$UPH&)D:&&2 E#(Q,_QEW_P<(, "1G [email protected] M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HQ.2 P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X,R],96YG [email protected]@-CDO4R T.
TECH

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

19h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to TECH / Bio-Techne Corp on message board site Silicon Investor.

NexOptic Technology Corp NexOptic Technology Corp NexOptic Technology Corp Technology Stocks u0026 Market Talk With Don Wolanchuk Technology Stocks u0026 Market Talk With Don Wolanchuk Technology Stocks u0026 Market Talk With Don Wolanchuk
Verde Agritech Verde Agritech Verde Agritech KULR Technology KULR Technology KULR Technology
Neptune Technologies u0026 Bioressources Inc. - NTB.V Neptune Technologies u0026 Bioressources Inc. - NTB.V Neptune Technologies u0026 Bioressources Inc. - NTB.V Biotech Valuation Biotech Valuation Biotech Valuation
StrikeForce Technologies StrikeForce Technologies StrikeForce Technologies NanoViricides - Nanobiotechnology NanoViricides - Nanobiotechnology NanoViricides - Nanobiotechnology
The *NEW* Frank Coluccio Technology Forum The *NEW* Frank Coluccio Technology Forum The *NEW* Frank Coluccio Technology Forum 2018 Biotech Charity Contest 2018 Biotech Charity Contest 2018 Biotech Charity Contest
CUSIP: 09073M104